A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Thyroid

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/thy.2008.0321PMID 19265494PMCID PMC2913806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

  2009cited by this paper
• Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

  2008cited by this paper
• Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Complications

  2007cited by this paper
• Changing Patterns in the Incidence and Survival of Thyroid Cancer with Follicular Phenotype—Papillary, Follicular, and Anaplastic: A Morphological and Epidemiological Study

  2007cited by this paper
• A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies

  2007cited by this paper
• Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

  2007cited by this paper
• Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

  2006cited by this paper
• Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches

  2006cited by this paper
• Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer.

  2006cited by this paper
• Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin

  2005cited by this paper
• A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer

  2005cited by this paper
• Anaplastic thyroid carcinoma

  2005cited by this paper
• A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck

  2005cited by this paper
• Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

  2005cited by this paper
• Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

  2005cited by this paper
• Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor

  2004cited by this paper
• Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy.

  2004cited by this paper
• Combretastatin A4 phosphate: background and current clinical status

  2004cited by this paper
• Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

  2004cited by this paper
• Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

  2003cited by this paper
• Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

  2003cited by this paper
• A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

  2002influential reference
• Targeting tumour vasculature: the development of combretastatin A4.

  2001cited by this paper
• Anaplastic thyroid carcinoma: a 50-year experience at a single institution.

  2001cited by this paper
• Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.

  2000cited by this paper
• Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas.

  2000cited by this paper
• Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

  1999cited by this paper
• In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

  1999cited by this paper
• Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.

  1999cited by this paper
• A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995

  1998cited by this paper
• Prognostic factors for thyroid carcinoma

  1997cited by this paper
• Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

  1997cited by this paper
• Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.

  1997cited by this paper
• Clinical multidrug resistance in cancer: a multifactorial problem.

  1996cited by this paper
• Molecular genetics of human thyroid neoplasms.

  1994cited by this paper
• In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub)

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Chemotherapy of thyroid carcinoma

  1987cited by this paper
• Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

  1974cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• The National.

  1892cited by this paper

• Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING.

  2025cites this paper
• Anaplastic Thyroid Carcinoma: A Contemporary Review of Challenges and Advances.

  2025cites this paper
• Modern Therapeutic Approaches in Anaplastic Thyroid Cancer: A Meta-Analytic Review of Randomised and Single Arm Studies on Efficacy and Survival

  2025cites this paper
• From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies

  2024cites this paper
• A novel life for antitumor combretastatins: Recent developments of hybrids, prodrugs, combination therapies, and antibody-drug conjugates.

  2024cites this paper
• Combretastatins A-4 and A-1 and their derivatives: Review

  2024cites this paper
• Combretastatin A-4 based compounds as potential anticancer agents: A review.

  2024cites this paper
• Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.

  2023cites this paper
• Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

  2023cites this paper
• The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer

  2023cites this paper
• Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility

  2023cites this paper
• Advances in targeted therapy for anaplastic thyroid carcinoma

  2022cites this paper
• Optochemical Control of Therapeutic Agents through Photocatalyzed Isomerization

  2022cites this paper
• Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cites this paper
• The Role of the Kinase Inhibitors in Thyroid Cancers

  2022cites this paper
• Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy

  2022cites this paper
• Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management

  2022cites this paper
• Thyroid Carcinoma, Version 2.2022

  2022cites this paper
• Phytochemicals in thyroid cancer: analysis of the preclinical studies

  2021cites this paper
• Advances in targeted therapy for anaplastic thyroid carcinoma.

  2021cites this paper
• Inhibiting parasite proliferation using a rationally designed anti‐tubulin agent

  2021cites this paper
• Targeted microbubbles carrying lipid-oil-Nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, Combretastatin A4.

  2021cites this paper
• Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

  2021cites this paper
• 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

  2021cites this paper
• Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics

  2021cites this paper
• Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer

  2021cites this paper
• Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.

  2021cites this paper
• Anaplastic thyroid cancer. Is there a light at the end of the tunnel?

  2020cites this paper
• Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review

  2020cites this paper
• Invited submission by the editor marek los vascular disrupting agents in cancer therapy.

  2020cites this paper
• Pharmacotherapeutic Botanicals for Cancer Chemoprevention

  2020cites this paper
• Design, synthesis, and evaluations of the antiproliferative activity and aqueous solubility of novel carbazole sulfonamide derivatives as antitumor agents.

  2020cites this paper
• The progress of the anticancer agents related to the microtubules target.

  2020cites this paper
• Microtubule-targeting agents and their impact on cancer treatment.

  2020cites this paper
• Recent advances in the management of anaplastic thyroid cancer

  2020cites this paper
• Cancer Chemoprevention by Natural Plant Products and Their Derivatives: Clinical Trials

  2020cites this paper
• Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4.

  2020cites this paper
• Plant natural products with anti-thyroid cancer activity.

  2020cites this paper
• Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies

  2020cites this paper
• Anaplastic Thyroid Carcinoma

  2019cites this paper
• New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents.

  2019cites this paper
• Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

  2019influential citation
• A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer

  2019cites this paper
• Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer

  2019cites this paper
• Treatment of a malignant peripheral nerve sheath tumor by intravenous administration of combretastatin A4-phosphate in a dog

  2018cites this paper
• A dose‐escalation study of combretastatin A4‐phosphate in healthy dogs

  2018cites this paper
• Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies.

  2018cites this paper
• ROLE OF TYROSINE KINASE INHIBITOR THERAPY IN ANAPLASTIC THYROID CANCER

  2018cites this paper
• Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Drug-Clinical Agent Molecular Hybrid: Synthesis of Diaryl(trifluoromethyl)pyrazoles as Tubulin Targeting Anticancer Agents

  2018cites this paper
• VARIOUS TECHNIQUES TO ASSESS THE ANTI-VASCULAR EFFECT OF A VASCULAR DISRUPTIVE AGENT ON THE PERFUSION OF A SOLID TUMOR IN A DOG

  2018cites this paper
• First-Line Therapy for Anaplastic Thyroid Cancer: Operation Versus Medical Management

  2018cites this paper
• Design of Carborane-Based Hypoxia-Inducible Factor Inhibitors

  2018cites this paper
• Combretastatin A4‐phosphate and its potential in veterinary oncology: a review

  2017cites this paper
• Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies

  2017cites this paper
• Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT

  2017influential citation
• Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents

  2017cites this paper
• Development of combretastatins as potent tubulin polymerization inhibitors.

  2017cites this paper
• Rapid Recurrence of Anaplastic Carcinoma: Advocacy towards Non-Surgery

  2017cites this paper
• Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.

  2017cites this paper
• A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.

  2017cites this paper
• Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents.

  2017cites this paper
• Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma

  2016cites this paper
• Pyridine Based Antitumour Compounds Acting at the Colchicine Site.

  2016cites this paper
• Emerging Targets in Photopharmacology.

  2016cites this paper
• Chemotherapy for Anaplastic Thyroid Cancer

  2016cites this paper
• Neue Ziele für die Photopharmakologie

  2016cites this paper
• Future Directions for Advanced Thyroid Cancer Therapy

  2016cites this paper
• Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside

  2016cites this paper
• Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications

  2016cites this paper
• Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

  2016cites this paper
• Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

  2016cites this paper
• Compuestos citotóxicos de origen vegetal y su relación con proteínas inhibidoras de apoptosis (IAP)

  2016cites this paper
• Fosbretabulin tromethamine in the treatment of thyroid cancer

  2016cites this paper
• Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors.

  2016cites this paper
• Early investigational tubulin inhibitors as novel cancer therapeutics

  2016influential citation
• Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy

  2016cites this paper
• Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

  2015cites this paper
• Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division

  2015cites this paper
• External Beam Radiotherapy for Thyroid Cancer

  2015cites this paper
• Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products

  2015cites this paper
• The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy

  2015cites this paper
• Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.

  2015cites this paper
• Survival in anaplastic thyroid cancer in relation to pre-existing goiter: a population-based study.

  2015cites this paper
• Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells

  2015cites this paper
• Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division

  2015cites this paper
• Genomic analysis of head and neck endocrine glands

  2015cites this paper
• Anaplastic Thyroid Carcinoma, Version 2.2015.

  2015cites this paper
• Combretastatins: More Than Just Vascular Targeting Agents?

  2015cites this paper
• An immunohistochemical investigation of the expression of somatostatin receptor subtypes – should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?

  2015cites this paper
• Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents

  2015cites this paper
• Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

  2015cites this paper
• Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer.

  2015cites this paper
• Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.

  2015cites this paper
• Pathologie moléculaire des carcinomes anaplasiques thyroïdiens : étude rétrospective à propos de 144 cas

  2015cites this paper
• An update on molecular biology of thyroid cancers.

  2014cites this paper
• Fosbretabulin for the treatment of anaplastic thyroid cancer.

  2014cites this paper
• Medical therapy for advanced forms of thyroid cancer.

  2014cites this paper
• Effects of the Tumor‐Vasculature‐Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels

  2014cites this paper